



Evolution of HCC



HER2 inhibition treatment



1. *In vitro* HER2 inhibition
with Transtuzumab in HER2-positive HCC cells (Figure 3,4)

Cell survival	Cell proliferation	EMT
-	↓ (10-20%)	↓↓↓

2. *In vivo* HER2 inhibition
with Transtuzumab in intrahepatic tumor in rats (Table S3)

Tumor size	Metastasis
↓↓ (40%)	↓↓↓ (60%)